McKesson Advances Specialty Leadership; Signs Agreement to Acquire Controlling Interest in PRISM Vision Holdings, LLC
McKesson (NYSE: MCK) has announced a definitive agreement to acquire an 80% controlling interest in PRISM Vision Holdings for approximately $850 million. PRISM Vision physicians will retain the remaining 20% interest. PRISM Vision is a premier provider of general ophthalmology and retina management services, operating with more than 180 providers across 91 office locations and seven ambulatory surgery centers.
The acquisition will be consolidated within McKesson's U.S. Pharmaceutical segment and is expected to be $0.20 to $0.30 accretive to McKesson's Adjusted Earnings Per Diluted Share in the first 12 months, growing to $0.65 to $0.75 by the end of the third year. The transaction aims to strengthen McKesson's position in retina and ophthalmology care, expand data and analytics capabilities, and enhance clinical research opportunities.
McKesson (NYSE: MCK) ha annunciato un accordo definitivo per acquisire un interesse di controllo dell'80% in PRISM Vision Holdings per circa $850 milioni. I medici di PRISM Vision manterranno il restante 20% di interesse. PRISM Vision è un fornitore di servizi di oftalmologia generale e gestione della retina di primo piano, con oltre 180 fornitori distribuiti in 91 sedi e sette centri chirurgici ambulatoriali.
L'acquisizione sarà consolidata all'interno del segmento Farmaceutico statunitense di McKesson e si prevede che porti un incremento di $0.20 a $0.30 agli Utili Per Azione Diluiti Adjustati di McKesson nei primi 12 mesi, crescendo fino a $0.65 a $0.75 entro la fine del terzo anno. L'operazione mira a rafforzare la posizione di McKesson nella cura della retina e dell'oftalmologia, espandere le capacità di dati e analisi, e migliorare le opportunità di ricerca clinica.
McKesson (NYSE: MCK) ha anunciado un acuerdo definitivo para adquirir un interés de control del 80% en PRISM Vision Holdings por aproximadamente $850 millones. Los médicos de PRISM Vision retendrán el 20% restante de interés. PRISM Vision es un proveedor de servicios de oftalmología general y manejo de retina de primer nivel, operando con más de 180 proveedores en 91 ubicaciones y siete centros de cirugía ambulatoria.
La adquisición se consolidará dentro del segmento farmacéutico de McKesson en EE.UU. y se espera que sea $0.20 a $0.30 accretivo a las ganancias ajustadas por acción diluida de McKesson en los primeros 12 meses, creciendo a $0.65 a $0.75 para el final del tercer año. La transacción tiene como objetivo fortalecer la posición de McKesson en el cuidado de retina y oftalmología, expandir las capacidades de datos y análisis, y mejorar las oportunidades de investigación clínica.
맥케슨 (NYSE: MCK)은 약 $8억 5천만에 PRISM Vision Holdings의 80% 지분 인수를 위한 최종 계약을 발표했습니다. PRISM Vision의 의사들은 나머지 20%의 지분을 보유할 것입니다. PRISM Vision은 91개의 사무소와 7개의 외래 수술 센터에서 180명 이상의 제공자가 활동하는 일반 안과 및 망막 관리 서비스의 주요 제공업체입니다.
이번 인수는 맥케슨의 미국 제약 부문 내에서 통합될 것이며, 첫 12개월 동안 맥케슨의 조정 후 희석 주당 수익에 $0.20에서 $0.30의 기여를 할 것으로 예상되며, 3년이 끝날 무렵에는 $0.65에서 $0.75로 성장할 것입니다. 이 거래는 맥케슨의 망막 및 안과 치료 분야의 위치를 강화하고, 데이터 및 분석 능력을 확장하며, 임상 연구 기회를 향상시키는 것을 목표로 하고 있습니다.
McKesson (NYSE: MCK) a annoncé un accord définitif pour acquérir un intérêt de contrôle de 80% dans PRISM Vision Holdings pour environ $850 millions. Les médecins de PRISM Vision conserveront le reste des 20% d'intérêt. PRISM Vision est un fournisseur de services de gestion de l'ophtalmologie générale et de la rétine de premier plan, opérant avec plus de 180 fournisseurs dans 91 bureaux et sept centres de chirurgie ambulatoire.
L'acquisition sera intégrée dans le segment pharmaceutique américain de McKesson et devrait être de $0,20 à $0,30 accretif aux bénéfices ajustés par action diluée de McKesson au cours des 12 premiers mois, atteignant de $0,65 à $0,75 d'ici la fin de la troisième année. La transaction vise à renforcer la position de McKesson dans le domaine des soins de la rétine et de l'ophtalmologie, à élargir les capacités de données et d'analytique, et à améliorer les opportunités de recherche clinique.
McKesson (NYSE: MCK) hat eine endgültige Vereinbarung zur Übernahme einer controlling Beteiligung von 80% an PRISM Vision Holdings für etwa $850 Millionen angekündigt. Die Ärzte von PRISM Vision behalten die verbleibenden 20% der Anteile. PRISM Vision ist ein führender Anbieter von allgemeinen Augenheilkunde- und Netzhautmanagement-Diensten und verfügt über mehr als 180 Anbieter in 91 Standorten und sieben ambulanten Operationszentren.
Die Übernahme wird in McKessons US-Pharma-Segment konsolidiert und wird voraussichtlich $0,20 bis $0,30 zu McKessons bereinigtem Ergebnis pro verwässerter Aktie im ersten Jahr beitragen, mit einem Wachstum auf $0,65 bis $0,75 bis Ende des dritten Jahres. Die Transaktion zielt darauf ab, die Position von McKesson im Bereich Netzhaut- und Augenheilkunde zu stärken, die Daten- und Analysefähigkeiten zu erweitern und die klinischen Forschungsgelegenheiten zu verbessern.
- Acquisition of 80% stake in PRISM Vision for $850 million strengthens specialty care portfolio
- Expected earnings accretion of $0.20-$0.30 per share in first year
- Projected earnings accretion increase to $0.65-$0.75 by end of third year
- Expansion into high-growth retina and ophthalmology sector
- Addition of 180+ providers, 91 office locations, and 7 surgery centers
- Significant capital expenditure of $850 million required
- Integration risks with existing operations
- Regulatory clearance still pending
Insights
McKesson's strategic acquisition of PRISM Vision marks a significant expansion into the lucrative ophthalmology and retina care market, representing a carefully calculated move to diversify its specialty healthcare portfolio. The
The deal's financial structure is particularly noteworthy for three reasons:
- The immediate EPS accretion of
0.20-0.30 in year one indicates strong cash flow generation potential - The projected
0.65-0.75 EPS accretion by year three suggests significant operational synergies and growth opportunities - The retention of a 20% stake by PRISM physicians ensures aligned interests and continuity of care
The ophthalmology market presents compelling growth drivers, including an aging population, increasing prevalence of eye disorders and advances in treatment options. PRISM's established network of 180+ providers and 7 surgery centers provides McKesson with immediate scale and infrastructure to capitalize on these trends.
McKesson's expertise in oncology practice management and clinical research positions them well to create value through:
- Enhanced data analytics and clinical research capabilities
- Strengthened relationships with biopharma partners
- Improved operational efficiencies and cost management
- Expanded distribution channels for specialty pharmaceuticals
This acquisition aligns with McKesson's broader strategy of building comprehensive specialty care platforms while leveraging its existing infrastructure and expertise in healthcare services distribution. The transaction should strengthen McKesson's competitive position in the growing specialty care market while providing meaningful financial returns.
Acquisition enhances McKesson’s capabilities as a national partner in retina and ophthalmology care
McKesson will purchase an
“The acquisition of PRISM Vision will allow McKesson to build on our leadership in community practice and specialty solutions, while building a platform to serve the high-growth area of retina and ophthalmology,” said Brian Tyler, chief executive officer of McKesson. “PRISM Vision has a strong track record and value proposition for community-based physicians and a strong leadership team focused on delivering superior retinal care, enhancing the provider experience and delivering innovative clinical research capabilities. We intend to develop a leading platform for retinal care, delivering differentiated solutions and value across providers, biopharma partners and patients. McKesson has a long track record of leading practice management and clinical research outcomes with our differentiated Oncology platform, and we are excited to leverage this expertise to serve the high-growth area of retina and ophthalmology. This will allow us to expand our suite of solutions and continue to pursue our purpose of advancing health outcomes for all.”
This transaction will enable McKesson to deliver on several key strategic objectives:
- Develop a leading retinal and ophthalmology platform, expanding McKesson’s differentiated value proposition, clinical services and distribution offerings. PRISM affiliated practices include more than 180 providers, 91 office locations and seven ambulatory surgery centers
- Expand data and analytics capabilities
- Further innovative investment in clinical research opportunities
- Deepen biopharma partnerships
“McKesson’s long history of supporting specialty physicians by emphasizing clinical quality and enhancing patients’ access to care, is completely aligned with the core values and culture of PRISM Vision Group,” said Dr. Steven Madreperla, chief executive officer of PRISM Vision. “We are thrilled to be able to bring together PRISM’s exceptional provider base and service delivery platform with McKesson’s deep expertise in care delivery to further develop and expand our eye care network together.”
Following completion of the transaction, PRISM Vision will be consolidated within McKesson’s
Cautionary Statements
Except for historical information, statements in this press release regarding McKesson’s proposed acquisition and related arrangements constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements. We encourage investors to read the important risk factors described in the company’s most recent Form 10-K filed with the Securities and Exchange Commission. These risk factors include, but are not limited to: we may be unable to obtain necessary regulatory approvals; we may not achieve expected outcomes from the transaction; we might be adversely impacted by delays or other difficulties, including related to the transactions described in this press release; we from time to time record significant charges from impairment to goodwill, intangibles and other assets or investments; we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events, economic events and other catastrophic events.
About McKesson
McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250203778374/en/
Investors
investors@mckesson.com
Media Relations
mediarelations@mckesson.com
Source: McKesson Corporation
FAQ
How much is McKesson paying for PRISM Vision Holdings?
What is the expected earnings impact of MCK's PRISM Vision acquisition?
How many locations does PRISM Vision operate?
What percentage of PRISM Vision will McKesson own after the acquisition?
Which McKesson segment will include PRISM Vision after the acquisition?
